期刊文献+

药物洗脱支架对冠心病合并2型糖尿病患者的临床疗效

Effect of drug-eluting stents on patients with type 2 diabetes and coronary artery disease
下载PDF
导出
摘要 目的:评价药物洗脱支架在冠心病合并2型糖尿病患者中的临床疗效。方法:68例冠心病合并2型糖尿病患者接受冠脉内原发病变药物洗脱支架置入(SES组);对照组(BS组)是从我科资料库中抽取的原发病变置入普通支架的56例冠心病合并2型糖尿病患者。结果:术后1年内随访结果SES组与BS组手术成功率相似(分别为97.1%与98.2%,P=1.00)。SES组与BS组累计1年内主要不良心脏事件发生率分别为19.1%与35.7%(P=0.037,OR=0.425,95%CI:0.188~0.961),再次血运重建率为10.3%与25.0%(P=0.03,OR=0.344,95%CI:0.128~0.925),死亡、急性心肌梗死无差异。结论:药物洗脱支架较普通支架显著降低糖尿病患者冠脉介入治疗的1年主要不良心脏事件。 Objective:To evaluate the clinical outcomes of patients with coronary artery disease and type 2 diabetes who underwent elective percutaneous coronary intervention. Methods: From December 2002, a policy of routine sirolimus-eluting stents(SES) implantation has been instituted in our hospital. During 2 years of enrollment, a total of 68 consecutive diabetic patients with coronary lesions were electively treated with SES (SES group). A similar group for comparison comprised 56 consecutive patients treated with bare metal stents in the preceding period (BS group). Results: After 1-year follow-up, the cumulative rate of major adverse cardiac events (death, myocardial in farction, and any repeat revascularization) was 19. 1% in the SES group versus 35.7% in the BS group (P=0. 037,OR=0. 425 ,95%CI: 0. 188-0. 961), mainly due to a marked reduction in the need for repeat revascularization(10.3% versus 25.0%, P = 0. 03 , OR = 0. 344,95% CI 0. 128 0. 925). Conclusions: Routine utilization of SES for diabetic patients significantly reduces the rate of adverse cardiac events at 1 year compared to bare metal .
出处 《国际心血管病杂志》 2006年第3期191-193,共3页 International Journal of Cardiovascular Disease
关键词 药物洗脱支架 冠心病 2型糖尿病 Sirolimus-eluting stents Coronary artery disease Type 2 diabetes mellitus
  • 相关文献

参考文献12

  • 1[1]Elezi S,Kastrati A,Pache J,et al.Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement[J].J Am Coll Cardiol,1998,32(7):1866-1873.
  • 2[2]Cutlip DE,Chauhan MS,Baim DS,et al.Clinical restenosis afet coronary stenting:perspectives from multicenter clinical trial[J].J Am Coll Cardiol,2002,40 (12):2082-2089.
  • 3[3]Abizaid A,Kornowski R,Mintz GS,et al.The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation[J].J Am Coll Cardiol,1998,32(3):584-589.
  • 4[4]Morice MC,Serruys PW,Sousa JE,et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization[J].N Engl J Med,2002,346 (23):1773-1780.
  • 5[5]Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J].N Engl J Med,2003,349 (14):1315-1323.
  • 6[6]Abizaid A,Costa MA,Blanchard D,et al.Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients.Insights from the RAVEL Trial[J],Eur Heart J,2004,25(2):107-112.
  • 7[7]Moussa I,Leon MB,Baim DS,et al.Impact of sirolimus-eluting stents on outcome in diabetic patients:a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy[J].Circulation,2004,109(19):2273-2278.
  • 8方跃华,沈卫峰,张瑞岩,张建盛.雷帕霉素洗脱支架对糖尿病患者经皮冠状动脉介入治疗的远期影响[J].中华心血管病杂志,2005,33(5):438-440. 被引量:5
  • 9[9]Schofer J,Schluter M,Gershlick AH,et al.Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries:double-blind,randomised controlled trial (E-SIRIUS).Lancet,2003,362 (9390):1093-1099.
  • 10[10]Cutlip DE,Baim DS,Ho KK,et al.Stent thrombosis in the modern era:a pooled analysis of multicenter coronary stent clinical trials[J].Circulation,2001,103(15):1967-1971.

二级参考文献9

  • 1The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 1997, 20: 1183-1197.
  • 2王彬尧 何奔 厉锦华.经皮冠状动脉腔内成形术和支架术[A].见:沈卫峰 主编.实用临床心血管疾病介入治疗学[C].上海:上海科学技术出版社,2004.106-116.
  • 3Laskey WK, Selzer F, Vlachos HA, et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry).Am J Cardiol, 2002, 90: 1062-1067.
  • 4Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement.J Am Coll Cardiol, 1998, 32: 1866-1873.
  • 5Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation.J Am Coll Cardiol, 1998, 32: 584-589.
  • 6Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med, 2002, 346:1773-1780.
  • 7Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.N Engl J Med, 2003, 349: 1315-1323.
  • 8Holmes DR, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.Circulation, 2004, 109: 634-640.
  • 9Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.Circulation, 2004, 109: 2273-2278.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部